Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial

Documenti analoghi

• Erratum to: Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial
  di: Siou, Kaitlin, et al.
  Pubblicazione: (2017)
• Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor–Based Combination Antiretroviral Therapy
  di: Papp, Eszter, et al.
  Pubblicazione: (2016)
• HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction
  di: Papp, Eszter, et al.
  Pubblicazione: (2015)
• Elevated Levels of Estradiol in Human Immunodeficiency Virus–Infected Pregnant Women on Protease Inhibitor–Based Regimens
  di: Balogun, Kayode A, et al.
  Pubblicazione: (2018)
• Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe
  di: Loutfy, Mona, et al.
  Pubblicazione: (2007)